GlassScriptPhysician profile
Yolande M Thomas
NPI 1174688998
$1,080.22
in general payments reported to CMS, 2019-2025
17 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $286 · 2022: $143 · 2023: $376 · 2024: $167 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $651.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $239.18 | 2022-2024 | Verquvo, Steglatro |
| Janssen Pharmaceuticals, INC | $209.88 | 2023-2024 | Xarelto |
| Amarin Pharma, INC. | $68.43 | 2021 | |
| Amgen INC. | $65.59 | 2021-2022 | |
| Csl Behring | $63.32 | 2024-2025 | Kcentra |
| Abbvie INC. | $62.03 | 2022-2024 | Dalvance |
| Medtronic, INC. | $47.67 | 2021-2023 | Mycarelink |
| Abiomed | $44.70 | 2022 | |
| Novartis Pharmaceuticals Corporation | $41.58 | 2025 | |
| Alnylam Pharmaceuticals INC. | $40.95 | 2021-2023 | Amvuttra |
| Boston Scientific Corporation | $40.57 | 2021 | |
| Octapharma USA, INC. | $34.92 | 2025 | Balfaxar |
| Abbott Laboratories | $28.53 | 2021 | |
| Lilly USA, LLC | $28.30 | 2024 | Mounjaro, Zepbound |
| Redhill Biopharma INC. | $23.92 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $20.64 | 2021 | |
| Phadia US INC. | $20.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yolande Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.